chrisvoncsefalvay/vaers-outcomes huggingface dataset:
electric shock on her left side; then palpitations; electric shock on her left side; then palpitations; This is a spontaneous report received from a contactable consumer (patient) reported for self that: A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as dose 2, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported) as dose 1, single for COVID-19 immunization. The patient got the vaccine on a Thursday, on Saturday and Sunday she felt like an electric shock on her left side, then palpitations on an unspecified date. The patient reported that she tried to call everywhere for a consultation with a cardiologist. Asks if someone can help her, she called the Centers for Disease Control and Prevention (CDC), they gave her a number. She called that number, and they gave her another number. States she is calling because she was told to call this number and press option 3. Call handler asks caller to spell her name. She declines. Says she was going to press three when the options came up on this call, but it was talking about the ingredients of the vaccine and she doesn't need to know those because she already had the vaccines. States that she called before and spent 25 minutes reporting the way she felt after the second Covid Vaccine. The events outcome was unknown.  Information on the lot/batch number has been requested.
itching, face and eye swelling, wheezing, H/A. Treated successfully with Epi X 2 and Benadryl.
Tooth pocket that appeared/it is painful and twinging, ( discomfort) "flinges" and throbbing; Hurt a bit; Arm was hurting more; This spontaneous case was reported by a consumer and describes the occurrence of TOOTH DISORDER (Tooth pocket that appeared/it is painful and twinging, ( discomfort) "flinges" and throbbing), PAIN (Hurt a bit) and VACCINATION SITE PAIN (Arm was hurting more) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination.     The patient's past medical history included Acid reflux (esophageal), Gastritis and Root canal procedure. Previously administered products included for Product used for unknown indication: Flu vaccine, Flu vaccine and Flu vaccine. Past adverse reactions to the above products included Burn with Flu vaccine; Numbness with Flu vaccine; and Pain with Flu vaccine. Concurrent medical conditions included Hypertension and Fibromyalgia. Concomitant products included AMLODIPINE for Heart disorder.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, the patient experienced TOOTH DISORDER (Tooth pocket that appeared/it is painful and twinging, ( discomfort) "flinges" and throbbing), PAIN (Hurt a bit) and VACCINATION SITE PAIN (Arm was hurting more). On 15-Mar-2021, TOOTH DISORDER (Tooth pocket that appeared/it is painful and twinging, ( discomfort) "flinges" and throbbing), PAIN (Hurt a bit) and VACCINATION SITE PAIN (Arm was hurting more) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication include beta blocker for heart condition. No treatment information was provided.
Adverse event was grey top was punctured on 3/11/22 and used on patient on 3/17/22. It went past the 12 hour time frame of use.  It was in Refrigerated state min temp 37.2 f max 40.6f .
anoxic brain damage;sz activity severe dehydration probable infarction of brain w/etiology evident of CT scan;
8/16 - parent Denies Adverse Reaction to 0.5mL dose given instead of 0.3 mL dose.
Noted redness of skin. Swelling of skin is noted. Pain of left upper arm at site of injections. Gradual increase in pain, warmth, and swelling. No fever.
Exasperated pain in osteoarthritc joints and bones.  All the fingers on my right hand- normally not painful, were affected.  My right hip and right knee flared in discomfort, which made walking difficult.  The neck ached, a dull headache resulting.   And fatigue, generalized. The next day, pain diminished, fatigue continued for two days.
December 29, 2019 Covid I got pneumonia I have x-rays.                          October 7, 2020 Covid again Mild experience June 10, 2021 Took Pfzir shot 1st dose.  3 weeks later I could not move out of bed. My heart became inflamed, Could not breath, I could not breath well in my throat. My rib cage felt like I had 100 pounds on it. I had fever & chills. My hand broke out is still broken out I have photos of a strange rash. I spent 5 weeks in bed. I lost 21 pounds. I lost appetite. I am still experiencing pain in my left side of my chest. Nasuea, dizzyness, fear, extreme fatigue I was given dye contrast and I stopped breathing. they had to put a tube down my throat to breath. 2nd time At a foot ball game. A bee stung me and I began to experience my throat closing up and I couldn't breath. I was treated at the hospital  anaphylaxis response.  I am now having mind fog issues, the rash has not gone away, and I have pain in my rib cage and a dry cough still.
discoloration at injection site after first dose of vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Apr2021 18:15 (Lot number: ER8731) as dose 1, single for covid-19 immunisation. Relevant medical history included: "high blood pressure" (unspecified if ongoing); "Obesity" (unspecified if ongoing), notes: No; "arthritis" (unspecified if ongoing). Concomitant medication(s) included: POTASSIUM ACETATE; METOPROLOL TARTRATE; SIMVASTATIN; DIOVAN HCT.  The following information was reported: VACCINATION SITE DISCOLOURATION (non-serious) with onset Apr2021, outcome "not recovered", described as "discoloration at injection site after first dose of vaccine". Therapeutic measures were not taken as a result of vaccination site discolouration.  Additional information: No other vaccine was administered in four weeks. Patient did not have covid prior vaccination nor tested post vaccination. Patient had no Known allergies.  No follow-up attempts are possible. No further information is expected.
Headache, joint soreness in knees, wrists, fingers, lower back pain, 101.2 fever (oral quick read).  Probably started overnight, noticed them at 7:30am.  Adverse events still in progress.  Hopefully, the information in items #20 and #21 can be updated after submission.
No adverse effects but patient was given (Moderna Bivalent Booster 6m-5y Covid-19) - Dark Pink Cap/Yellow Border (dose 0.20) on 4/28/23.  After. having one dose of (Moderna Monovalent Peds 6m-5y Covid-19) - Blue Cap/Magenta Border on 3/22/23. Patient should have received single dose 0.25 mL on 4/28/23.
facial assymetry, Drooping of unilateral eye/corner of mouth.  Only able to close one eye, other has to be taped shut at night. 12/12/07-records received-11/9/07-Bell's Palsy-presented with C/O pain left side of mouth and twitching of face. Facial drooping on left began 4 days after vaccination. Unable to close her left eye. In office no facial twitching noted.
12/31 visited physician office and appeared to have COVID toes. Received vaccination on 12/21/20. on 12/31 had no fever or related symptoms. Had lesions that are not painful or itchy. they started 3 days after vaccination, not spreading with worse redness on the 30th than the 31st. patient was covid negative and did not receive the 2nd dose.
Hands swollen painful and red; Hands swollen painful and red; Hands swollen painful and red; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Hands swollen painful and red), PERIPHERAL SWELLING (Hands swollen painful and red) and ERYTHEMA (Hands swollen painful and red) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Hands swollen painful and red), PERIPHERAL SWELLING (Hands swollen painful and red) and ERYTHEMA (Hands swollen painful and red). At the time of the report, PAIN IN EXTREMITY (Hands swollen painful and red), PERIPHERAL SWELLING (Hands swollen painful and red) and ERYTHEMA (Hands swollen painful and red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported. Treatment information not reported.
Second Shingles shot. Aches, chills, headache, insomnia. No problem with the first shot
Pain and soreness following administration x 2 months. Impaired movement of arm continued to present.
11/1/17 at 12:15pm dizzy and nauseous 12:20pm Arm where shot was given very painful 12:30pm Got up to go to restroom-fainted-landed on tile floor. Broke left cheek in 3 pieces which now have titanium plates. 245pm was taken to ER via ambulance 11/8/17 Had surgery to put the plates in my face Still recovering.
L deltoid red/tender, swollen, feverish to touch. Measuring approx. 8"X2.5" Fever 101, per clt. All S&S much decreased upon conversation w/ clt. on 12/20/2012, after using alternating moist heat/cold pks, ibuprofen and Keflex X 3 days.
Swelling and pain of the left arm from shoulder down to the elbow. For about 24 hours had temperature of 100.9.
warm to the touch; felt very tired; little swelling and redness at the injection site; little swelling and redness at the injection site; Big rash which grew twice in size overnight.; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Feb-2021 and was forwarded to Moderna on 23-Feb-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of VACCINATION SITE WARMTH (warm to the touch), VACCINATION SITE RASH (Big rash which grew twice in size overnight.), FATIGUE (felt very tired), VACCINATION SITE ERYTHEMA (little swelling and redness at the injection site) and VACCINATION SITE SWELLING (little swelling and redness at the injection site) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 013M20A) for COVID-19 vaccination.     Concurrent medical conditions included Bee sting.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Feb-2021, the patient experienced VACCINATION SITE RASH (Big rash which grew twice in size overnight.). On an unknown date, the patient experienced VACCINATION SITE WARMTH (warm to the touch), FATIGUE (felt very tired), VACCINATION SITE ERYTHEMA (little swelling and redness at the injection site) and VACCINATION SITE SWELLING (little swelling and redness at the injection site). The patient was treated with METHYLPREDNISOLONE for Rash, at a dose of 4 mg. On 16-Feb-2021, VACCINATION SITE RASH (Big rash which grew twice in size overnight.) had resolved. At the time of the report, VACCINATION SITE WARMTH (warm to the touch), FATIGUE (felt very tired), VACCINATION SITE ERYTHEMA (little swelling and redness at the injection site) and VACCINATION SITE SWELLING (little swelling and redness at the injection site) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) dosing remained unchanged.       Concomitant product use was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Additional AEs, medication taken, pt initial, 2nd dose information added
patient completed moderna as primary series but requested jansenn as booster. but moderna was given in error
Night that shots given presented to ED Got up,  felt nausea, then recalls feeling lightheaded and as if he was about to pass out. Next recalls being on the ground, mother witnessed that he hit his head, was briefly shaking, then regained consciousness and acting normal soon after this
Patient says she had severe nausea and vomiting and weakness and diarrhea for 6-8 hours.
the loss of hair of half of her head; Unable to move/ could not move due to general fatigue; Slight body aches; General fatigue; Chills/ Shivers; High fever; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (the loss of hair of half of her head), MOBILITY DECREASED (Unable to move/ could not move due to general fatigue), PAIN (Slight body aches), FATIGUE (General fatigue) and CHILLS (Chills/ Shivers) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046G21A and 045B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 12-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In September 2021, the patient experienced ALOPECIA (the loss of hair of half of her head), MOBILITY DECREASED (Unable to move/ could not move due to general fatigue), PAIN (Slight body aches), FATIGUE (General fatigue), CHILLS (Chills/ Shivers) and PYREXIA (High fever). At the time of the report, ALOPECIA (the loss of hair of half of her head), MOBILITY DECREASED (Unable to move/ could not move due to general fatigue), PAIN (Slight body aches), FATIGUE (General fatigue), CHILLS (Chills/ Shivers) and PYREXIA (High fever) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Significant but not extreme vertigo lasting about half an hour.  Several weeks later, more moderate, more persistent vertigo returned and persisted for several weeks off and on, accompanied by extreme fatigue and tinnitus.  Because I had had one previous, weeklong episode of severe vertigo in 2018, a specialist diagnosed me with probable Meniere?s disease based on this second episode that began about a month after my Covid19 Janssen vaccine.  It is not my belief that it was necessarily caused by the vaccine, but I thought I should report the information.
after flu shot in Oct 2020 and 2 covid shots in Mar/Apr 2021, I developed frozen shoulder.  The pain has been progressively getting worse, went to my doctor, he ordered MRI and it confirmed the frozen shoulder.  This Friday I go for fluroscopic steroid injection  and then start physical therapy in Nov.  Extremely painful and limiting, and is especially bad at night.  Only relief I currently get is in the bathtub
Within 5 minutes of receiving the shot- began with itching in throat, hives, tongue  and lips swelling, mouth itching, burning felling all over Treatment- SubQ epinephrine, Depomedrol IM
PAIN IN ARM, VERY RED AND SWOLLEN. REDNESS SPREAD OVER AREA OF ARM.  JOINT PAIN.
they all came down with COVID in a week; they all came down with COVID in a week; This is a spontaneous report from a contactable physician. This physician reported similar events for 4 patients. This is 2nd of 4 reports. An elderly patient of an unspecified age and gender received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) (lot number/expiration date: not provided), via an unspecified route of administration, an unknown date as a single dose for COVID-19 vaccination. Relevant medical history and concomitant medication were not provided. On an unknown date, the patient came down with COVID in a week of vaccination. The outcome of the event came down with COVID in a week was unknown. The reporting physician stated that he doesn't think that them getting the vaccine and having COVID is related, he thinks it is a coincidence.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.; Sender's Comments: Based on the mechanism of action of BNT162B2 vaccine, it is unlikely the patient would have fully developed immunity for the vaccine to be effective, due to the number of days passed since the vaccine was given (a week in this case). However, a causal relationship between event "came down with COVID in a week of vaccination" (coded to Drug ineffective / COVID-19) and BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) cannot be completely excluded.,Linked Report(s) : US-PFIZER INC-2021064977 as same reporter/drug/AE/different patients.
Discharge Provider: MD Primary Care Provider: MD Admission Date: 5/1/2022 Discharge Date: 5/3/2022  PRESENTING PROBLEM: Pneumonia due to COVID-19 virus COVID-19   HOSPITAL COURSE: Patient is a 74 y.o. female with past medical history significant for hypertension, hyperlipidemia, hypothyroidism, coronary artery disease, HFrEF with ejection fraction 25%, ischemic cardiomyopathy, history of myocardial infarction, diabetes mellitus type 2, history of CVA/TIA, CKD stage IIIB, obstructive sleep apnea on CPAP, parkinson's disease, dementia, mixed anxiety and depression, additional comorbidities who presented to the emergency department for generalized weakness.  Per family at bedside patient initially had chest discomfort on Friday 4/29/2022 midsternal radiating to her left neck; patient was given nitroglycerin with mild relief.  Throughout the night patient developed fever and chills, family went to urgent care and was tested for COVID and was found to be COVID-19 positive on April 30, 2022.  Per family at bedside she has had low-grade fevers, generalized weakness, decreased appetite and decreased intake of fluids.  Daughter also states she has had loose stools.  Patient is vaccinated against COVID-19 with booster.   In the ED, vital signs reviewed in the emergency department, patient was mildly hypertensive, otherwise within acceptable range.  Patient extensive diagnostic workup consisting of complete blood count:  WBCs 4.5, hemoglobin 11.7, hematocrit 38.2, platelets 189, differential within acceptable limits.  CMP:  Sodium 140, potassium 5.2, chloride 106, bicarb 25, anion gap 9, creatinine 1.63, BUN 42, GFR 31, liver enzymes within acceptable limits.  Initial troponin 123, 2nd troponin 116. One-view chest x-ray:  No acute pulmonary infiltrate with chronic elevation of left hemidiaphragm.  Rapid COVID-19 positive.  Limited echocardiogram reveals ejection fraction 25%, right ventricle function cannot be assessed due to poor imaging quality. NM lung perfusion was negative for PE. She was given 324 mg of aspirin, normal saline 250 bolus, and supportive treatment.  Emergency room department provider spoke with Cardiology concerning elevated troponins and EKG changes, which felt at this time the patient is not a candidate for interventional therapy.  Patient mildly improved in the emergency department treatment plan.  She was admitted for further medical management. Home lasix was held and AKI on CKD 3 improved. She was evaluated by Cardiology and recommended outpatient follow up and they will arrange outpatient palliative care as well. She was evaluated by PT/OT and home health services were arranged. It was recommended that the patient hold lasix until 5/6/2022 as her oral intake improves as she recovers from COVID 19. She should follow up with her PCP as well. She was discharged home in stable condition on 5/3/2022.
Autoimmune, sjogrens syndrome, mixed connective tissue disorder, fibromyalgia, TIA, neuropathy, inflammation of joints, migraine disorder, cognitive decline
no adverse event; VARIVAX experienced temperature excursion and was administered; This spontaneous report as received from a vaccine coordinator refers to a patient of unknown age and gender. On 08-APR-2022, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) (Lot # U015685 exp date 18-MAY-2023) (dose and route not reported). Concomitant therapies included sterile diluent. The temperature of excursion was -13.86 °C for a time frame of 4 hours. There was no previous temperature excursion.
Patient indicated no reactions to previous flu shots. After administering the flu shot the site swelled up to the size of a grape. The patient was feeling fine, we gave her a 25 mg BENADRYL capsule. Told pt to wait 15 min, I went to check in her and she had left.
Headache, fever, nausea, pain in joins and skin, vomiting, fatigue, fever, shakes and chills
Patient had syncopal episode. Continued lightheadedness, abdominal discomfort, nausea. Patient with hypotension and bradycardia. Transferred via EMS to hospital.
Severe stroke caused by blood clot. She is still in onsite rehab and not able to speak or walk.
Oct 1, 2013 client received vaccine per pt Oct 4, 2013 small rash on arms started, as weekend continued the rash spread to trunk, arms, legs, and neck. Oct 8, 13 client referred to clinic for dr.
Swelling of face that affected mostly chin, ears, and eye pads. Hot to the touch and bright red. Rash at injection site for over two weeks. Lump under arm for over two weeks, painful to touch. Altered sense of smell still present after two months.
10/31 Day 1 - threw up (vomiting), drowsy, swollen, line going toward heart. 11/1 Day 2 - Saw Dr. and gave her levothyroxine and going back for follow up 11/4.
Breakthrough case admission 1/18/2022 Pfizer Lot3 FD7218 2/8/22 Pfizer Lot# FK9896
This case was reported by a consumer via call center representative and described the occurrence of chills in a 68-year-old female patient who received SHINGRIX for prophylaxis. On 18th March 2019, the patient received the 2nd dose of SHINGRIX. On 18th March 2019, less than a day after receiving SHINGRIX, the patient experienced chills. On 19th March 2019, the patient experienced fever. On an unknown date, the outcome of the chills was recovered/resolved and the outcome of the fever was not recovered/not resolved. It was unknown if the reporter considered the chills and fever to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left arm. The patient experienced chills after receiving SHINGRIX and on the day of reporting the patient had a low grade fever. The reporter consented to follow up.
Patient received first dose of Pfizer from different facility and another facility gave 2nd and 3rd doses to patient. System was not checked between second and third dose.